BioMérieux snags BioFire Diagnostics in $450M buy
Tracy Staton Chairman and CEO Jen-Luc Belingard envisions using BioFire's Salt Lake City, UT, headquarters and 500-plus employees as foundations for growth in molecular diagnostics. FiercePharma News
View ArticleInotek snags $21M for PhII glaucoma drops
Damian Garde Lexington, MA's Inotek has pulled down a $ 21 million round to advance its lead product, designed to ease in-eye pressure for glaucoma patients. FierceBiotech News
View ArticleBoehringer snags EU nods for COPD drug as FDA awaits
Damian Garde Boehringer Ingelheim has won over European regulators with its latest COPD therapy, following a favorable FDA panel vote that set the stage for U.S. approval and entrance into a huge but...
View ArticleRoche snags FDA nod for ‘breakthrough’ Rituxan successor
Damian Garde Just as biosimilar competition creeps up on blockbuster Rituxan, Roche and partner Biogen Idec have won FDA approval for the cancer drug's heir, marking the first success story for the...
View ArticleTiGenix snags $13.7M for Phase III cell therapy
Damian Garde Belgium's TiGenix has hauled in about $ 13.7 million in debt financing, piling up cash as it works through Phase III with a stem cell treatment. FierceBiotech News
View ArticleSage snags $38M from A-list VCs to bankroll its seizure drugs
Damian Garde Cambridge, MA's Sage Therapeutics has hauled in a $ 38 million Series C, convincing a who's-who of biotech investors to pitch in as it pushes forward with a portfolio of central nervous...
View ArticleIsarna snags another $7.6M to advance its cancer immunotherapy
Damian Garde After shifting its focus from antisense therapies to immuno-oncology last year, Germany's Isarna Therapeutics has pulled down $ 7.6 million to jump-start the development of some...
View ArticleMore M&A: Forest snags Furiex for $1.1B as Meda stiff-arms Mylan’s $9B bid
Tracy Staton Pharma's M&A fever may be most obvious among the industry's biggest players, but smaller companies are making their own bids, transformational and otherwise. FiercePharma News
View ArticleSpark snags a ‘breakthrough’ tag for its Phase III gene therapy
Damian Garde Gene therapy startup Spark Therapeutics has picked up the FDA's coveted breakthrough-therapy designation for its lead candidate, a one-time treatment that promises a permanent solution...
View ArticleIconic Therapeutics snags $40M for eye disease R&D
Damian Garde South San Francisco's Iconic Therapeutics raised $ 40 million in Series C cash to support its work on treatments for eye cancer, moving toward clinical trials with its ocular melanoma...
View ArticleAbbVie and Roche’s cancer drug snags another ‘breakthrough’ tag
Damian Garde AbbVie and Roche's cancer drug venetoclax, awaiting FDA approval, picked up another breakthrough therapy nod from the agency for its potential as part of a combination treatment for...
View ArticleGenentech snags a PhII-ready IL-33 asthma/COPD drug from Amgen
John Carroll Genentech has moved to the head of a small group of players in the anti-inflammatory arena, bagging rights to an antibody that scrambles the connection between IL-33 and the ST2...
View Article
